CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2 enrolled
Drug / intervention
89Zr-J591 +3 moredrug
Likely dose
89Zr-J591 19mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02410577
NCT02410577N/ACompleted
CompareCT.gov

A Pilot Study of 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 7, 2015·Updated Mar 19, 2019

In Brief

A clinical study evaluating 89Zr-J591, PET/CT Scan, and 2 other interventions for Glioblastoma. Completed, enrolled 2 participants across 1 site.

Detailed Summary

The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsWeill Medical College of Cornell University

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 7, 2015
Enrollment StartApr 1, 2015
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.2 years ago

Interventions

89Zr-J591drug

The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.

PET/CT Scandevice

MRIdevice

Blood drawother

Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.